Safety Initial dose of study therapy through 30 days post last dose of study therapy [clinicaltrials_resource:7ebf5e3976ea71d2f0c3999f4c5989cc]
1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Safety Initial dose of study therapy through 30 days post last dose of study therapy [clinicaltrials_resource:7ebf5e3976ea71d2f0c3999f4c5989cc]
1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
Bio2RDF identifier
7ebf5e3976ea71d2f0c3999f4c5989cc
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7ebf5e3976ea71d2f0c3999f4c5989cc
measure [clinicaltrials_vocabulary:measure]
time frame [clinicaltrials_vocabulary:time-frame]
Initial dose of study therapy through 30 days post last dose of study therapy
description
1.2mg in combination with adju ...... nce for each additional cycle.
identifier
clinicaltrials_resource:7ebf5e3976ea71d2f0c3999f4c5989cc
title
Safety Initial dose of study therapy through 30 days post last dose of study therapy
@en
type
label
Safety Initial dose of study t ...... f5e3976ea71d2f0c3999f4c5989cc]
@en